Physician profile
Jennifer A Ganem
NPI 1255340469
$158,273.28
in general payments reported to CMS, 2019-2025
8 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,429 · 2022: $32K · 2023: $41K · 2024: $45K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $34K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $18K · Consulting Fee: $9,915 · Food and Beverage: $4,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $34,189.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $31,576.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,425.00 |
| Travel and Lodging | $17,712.99 |
| Consulting Fee | $9,915.00 |
| Food and Beverage | $4,917.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $95,428.44 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $30,359.96 | 2023-2025 | Auvelity |
| Noven Pharmaceuticals, INC. | $29,901.22 | 2023-2024 | Xelstrym |
| Noven Therapeutics, LLC | $1,155.00 | 2025 | Xelstrym |
| Otsuka America Pharmaceutical, INC. | $633.84 | 2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $313.00 | 2021 | |
| Abbvie INC. | $278.79 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $203.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ganem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.